<DOC>
	<DOCNO>NCT00174837</DOCNO>
	<brief_summary>The trial compare efficacy safety concomitant chemoradiation tirapazamine , cisplatin radiation versus cisplatin radiation .</brief_summary>
	<brief_title>TRACE : Tirapazamine-Radiation And Cisplatin Evaluation</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Tirapazamine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Previously untreated squamous cell carcinoma oral cavity , oropharynx , hypopharynx , larynx . Stage III IV disease ( exclude T1N1 , T2N1 metastatic disease ) . Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 . Absolute neutrophil count least 1.5 X 10^9/L , platelet count least 100 X 10^9/L , hemoglobin &gt; 9g/dL . Serum bilirubin &lt; 1.25 time upper limit normal ( ULN ) aspartate aminotransferase ( AST ) /alanine transaminase ( ALT ) &lt; 2.5 time ULN . Calculated creatinine clearance ( CockcroftGault ) &gt; 55 mL/min . Metastatic Disease Primary cancer nasal paranasal cavity nasopharynx Significant intercurrent illness interfere Chemotherapy Radiation Therapy trial Symptomatic peripheral neuropathy &gt; grade 2 Clinically significant hearing impairment Significant cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Tirapazamine</keyword>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Radiation</keyword>
</DOC>